



August 14, 2021

**The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001**

Dear Sir,

Subject: Outcome of the Board Meeting.

This is with reference to our letter dated 03rd August 2021.

At the meeting of the Board of Directors of the company held on 14th August 2021 the following decisions have been taken:

- 1) It was decided to hold the 31st Annual General Meeting on Thursday the 30th September 2021 at 10.00 A.M. through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM").
- 2) The Register of Members and Share Transfer Books of the Company will remain closed from Monday the 27th September 2021 to Wednesday the 29th September, 2021 (both days inclusive).
- 3) Unaudited financial results (Standalone and Consolidated) of the company for the quarter ended on 30.06.2021 alongwith the Limited Review Report (Standalone and Consolidated) by the Statutory Auditors of the Company.

This is for your information and records.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED

**KOTESWARA
RAO KOLLIPARA**

Digitally signed by KOTESWARA RAO KOLLIPARA
DN: c=IN, o=Personal,
2.5.4.20=7786ea9961b451563dbae379b601f3cc2ce2237c0ee4
77e24c52e-f02f1, postalCode=500033, st=Telangana,
serialNumber=f3cc5121b2886c11e49f7413ecbda851fcbad50
b509f6b0726f1b6104b43, cn=KOTESWARA RAO KOLLIPARA
Date: 2021.08.14 11:51:28 +05'30'

**DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR**

Encls : as above

TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollarum, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Audited)	31.03.2021 (Audited)
1	Revenue from operations	-	130,000	-	1,695,499
2	Other income (net)	438,470	1,281,417	438,470	2,668,984
3	Total income (1 + 2)	438,470	1,411,417	438,470	4,364,483
4	EXPENSES				
	Cost of materials consumed	-	227,039	42,078	429,068
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	60,919	179,212	-	179,212
	Employee benefits expense	655,821	319,469	732,873	2,459,236
	Finance costs	566,950	665,680	665,681	2,662,723
	Depreciation and amortisation expense	24,705,193	24,783,413	24,742,519	99,080,463
	Other expenses	566,326	1,299,474	624,383	3,885,247
	Total expenses	26,555,209	27,474,287	26,807,534	108,695,949
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(26,116,739)	(26,062,870)	(26,369,064)	(104,331,466)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(26,116,739)	(26,062,870)	(26,369,064)	(104,331,466)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(26,116,739)	(26,062,870)	(26,369,064)	(104,331,466)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(26,116,739)	(26,062,870)	(26,369,064)	(104,331,466)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	75,770,000	75,770,000	75,770,000	75,770,000
	Basic (Rs.)	(0.34)	(0.34)	(0.35)	(1.38)
	Diluted (Rs.)	(0.34)	(0.34)	(0.35)	(1.38)

Notes:

1. TrabiORAL & Intra-Nasal delivery:

(a) We are waiting for the results of a study conducted on a drug belonging to a large pharma company formulated on the TrabiORAL delivery technology.

(b) The management is undertaking relevant steps for the planned launch of Oral/Intra-nasal Insulin (**βi**) to serve animal healthcare division (**βi-a**) before the end of 2021-22 and for human usage (**βi-h**) in 2022-23.

2. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

3. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th August 2021.

For TRANSGENE BIOTEK LIMITED

KOTESWARA

RAO KOLLIPARA

Digitally signed by KOTESWARA RAO KOLLIPARA
DN: cn=K, o=Personal,
2.5.4.20=7786aea9961b451565dbae379bf601f3cc2ce223;
77cDe47fa24c02ac42bf1, postalCode=500033,
st=Telangana,
serialNumber=f3cc51231b286c11e40f17415ecbca85f5b;
badc50b5b6f9ed02b91b6104b43, cn=KOTESWARA RAO
KOLLIPARA

Dr.K.Koteswara Rao

Managing Director

Date: 14.08.2021

Place:Hyderabad

TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollarum, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Audited)	31.03.2021 (Audited)
1	Revenue from operations	-	130,000	-	1,695,499
2	Other income (net)	438,470	1,281,417	438,470	2,668,984
3	Total income (1 + 2)	438,470	1,411,417	438,470	4,364,483
4	EXPENSES				
	Cost of materials consumed	-	227,039	42,078	429,068
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	60,919	179,212	-	179,212
	Employee benefits expense	655,821	319,469	732,873	2,459,236
	Finance costs	566,950	665,680	665,681	2,662,723
	Depreciation and amortisation expense	24,705,193	24,783,413	24,742,519	99,080,463
	Other expenses	566,326	1,314,845	624,383	3,900,618
	Total expenses	26,555,209	27,489,658	26,807,534	108,711,320
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(26,116,739)	(26,078,241)	(26,369,064)	(104,346,837)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(26,116,739)	(26,078,241)	(26,369,064)	(104,346,837)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(26,116,739)	(26,078,241)	(26,369,064)	(104,346,837)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(26,116,739)	(26,078,241)	(26,369,064)	(104,346,837)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	75,770,000	75,770,000	75,770,000	75,770,000
	Basic (Rs.)	(0.34)	(0.34)	(0.35)	(1.38)
	Diluted (Rs.)	(0.34)	(0.34)	(0.35)	(1.38)

Notes:

1. TrabiORAL & Intra-Nasal delivery:

(a) We are waiting for the results of a study conducted on a drug belonging to a large pharma company formulated on the TrabiORAL delivery technology.

(b) The management is undertaking relevant steps for the planned launch of Oral/Intra-nasal Insulin (**Bi**) to serve animal healthcare division (**Bi-a**) before the end of 2021-22 and for human usage (**Bi-h**) in 2022-23.

2. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

3. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th August 2021.

For TRANSGENE BIOTEK LIMITED

KOTESWARA RAO
KOLLIPARA

Dr.K.Koteswara Rao

Managing Director

Date: 14.08.2021

Place:Hyderabad

Digitally signed by KOTESWARA RAO KOLLIPARA
DN: cn=K, o=Personal,
2.5.4.20=77Mee994b451563dbae379e8601f3cc22377cdee47ba24c02
a0f28f7, postalCode=500603, st=Telangana,
serialNumber=f2cc51231b288c11e40917413ecb0ba851f6ad4c52b2696d0f
bf16104b43, cn=KOTESWARA RAO KOLLIPARA
Date: 2013.08.14 14:37:05 +05'30'




Limited Review Report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 30 June 2021 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities

Name of the entity	Relationship
1. Transgene Biotek HK Limited	Subsidiary
2. PerOral Bio Private Limited	Subsidiary



5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial results of two subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 June 2021, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates
Chartered Accountants
FR No. 010114S


Manisha Dubey
Proprietor
M No. 212664
Place: Hyderabad
Date: 14.08.2021



Unique Document Identification Number (UDIN) for this document is
21212664AAAACK1110



Limited review report

To,

The Board of directors

M/s. Transgene Biotek Limited

Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 30 June 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" - ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates

Chartered Accountants

FRN: 010114S

Manisha Dubey

Proprietor

M No. 212664

Place: Hyderabad

Date: 14.08.2021



Unique Document Identification Number (UDIN) for this document is

21212664AAAACK1110